Metabolic Dysfunction-Associated Steatotic Liver Disease related Hepatocellular Carcinoma
Conditions
Interventions
Observation group:None
Sponsors
the First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; 2. Hepatic steatosis confirmed by radiology (abdominal ultrasound, CT, MRI, CAP >= 248 dB/m, or MRI-PDFF or MRS hepatic fat fraction >= 5%) or histology (fatty change involving >= 5% of hepatocytes) and HCC diagnosis; 3. At least one cardiometabolic risk factor (overweight/obesity, abnormal blood glucose or type 2 diabetes, dyslipidemia, abnormal HDL cholesterol, abnormal blood pressure); 4. Clinical outcomes can be determined through medical record review or a reliable database.
Exclusion criteria
Exclusion criteria: 1. Evidence of other liver diseases such as positive hepatitis B surface antigen or alcoholic liver disease at baseline or during follow-up; 2. Positive hepatitis C virus antibody (unless HCV RNA is negative and untreated, or SVR achieved >=3 years prior to baseline MRI); 3. HIV infection at baseline or during follow-up; 4. Secondary causes of fatty liver (such as use of systemic steroids, tamoxifen, or methotrexate); 5. History of other malignant tumors at baseline; 6. History of other malignant tumors before baseline (unless remission =5 years).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ovall Survival;Recurrence-free Survival; | — |
Countries
China
Contacts
Public ContactMinghua Zheng
the First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed